Clinical trial
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
NCT00570713 is registered in ClinicalTrials.gov with Morphotek as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
- Lead sponsor
- Morphotek
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2007
- Completion date
- December 31, 2009
- Enrollment
- 155 (actual)
- Sites
- 45
Conditions
As the registry lists them; a condition with its own page is linked.
pancreatic cancer